Safarpour Ali Reza, Askari Hassan, Ejtehadi Farshid, Azarnezhad Asaad, Raeis-Abdollahi Ehsan, Tajbakhsh Amir, Abazari Mohammad Foad, Tarkesh Firoozeh, Shamsaeefar Alireza, Niknam Ramin, Sivandzadeh Gholam Reza, Lankarani Kamran Bagheri, Ejtehadi Fardad
Department of Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz 7134814336, Iran.
The Princess Alexandra Hospital HNS Trust, Harlow, Essex CM20 1QX, United Kingdom.
World J Gastrointest Pathophysiol. 2021 Sep 22;12(5):84-105. doi: 10.4291/wjgp.v12.i5.84.
Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.
胆管癌(CCA)是一种在全球发病率不断上升的癌症,起源于胆管上皮细胞即胆管细胞。肿瘤起病隐匿,具有高级别肿瘤、预后差和复发风险高的特点。肝移植已被广泛接受为胆管癌的一种治疗选择。肝移植有望作为不可切除肝门部胆管癌和肝内胆管癌的姑息性和根治性治疗发挥关键作用。本研究的目的是确定哪些胆管癌病例应接受肝移植而非切除术,尽管报道的移植后复发率平均约为20%。本综述还旨在突出胆管癌的分子研究前沿以及胆管癌肝移植的方向。